However, it lacks the clinical trial data and regulatory approval of GLP-1 agonists, and its effects may be more modest
Description 5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes NAD+ precursors and is reported to be elevated in aged adipose tissue, obese skeletal muscle, and certain tumor types
The extensive safety database across multiple clinical trials and animal toxicology studies provides reassurance about AOD-9604s tolerability and absence of serious adverse effects
GLP-1 medications work mainly through appetite suppression and slower gastric emptying
Serious neuropsychiatric and neurological problems can develop, if left untreated
At this time, we do not accept insurance